67P Blood cell gene expression and clinical characteristics in advanced non-small cell lung cancer with immune-related adverse events

Immune checkpoint inhibitors (ICI) have improved the prognosis of non-small-cell lung cancer (NSCLC) but can also cause immune-related adverse events (irAEs), which be life-threatening and a complex management. Currently, there is need for molecular clinical markers to predict irAEs occurrence outcome. Clinical characteristics 762 patients with stage IV NSCLC receiving first- or second-line PD-(L)1 were analyzed. Additionally, blood samples 8 analyzed at baseline (BL) time toxicity (TT) in comparison matched control from similar ICI exposure, no irAEs. The expression 12 genes involved immune response (GATA3, TBX21, MKI67, CD247, FAS, FASLv1, FOXP3, GzmB, IFNγ, PD1, PRF1, RORgt) was absolutely quantified PAXgene RNA using RT-PCR plasmid standards. IrAEs occurred 176/762 cases (23%), frequency monotherapy chemoimmunotherapy (24% vs. 22%). CTCAE severity grade 1 11%, 2 41%, 3 37%, 4 10%, lethal (1%). Frequently affected endocrine glands (21%), lungs (17%), musculoskeletal system colon (15%) liver (15%). All other organs less commonly showed significant association better ECOG performance status (28% 18% PS 0 1, p = 0.006), PD-L1 positivity (25% 14%, 0.009), lower neutrophil-to-lymphocyte ratio (NLR, 28% 19% median 6.2 as cut-off, 0.004). Blood cell gene expressions slightly higher 7/12 immunologically relevant TT, 11/12 BL, not significantly different (p≥0.07). No substantial changes noted between BL TT each group (mean fold change 0.82, controls 0.84, ≥0.07). under occur more frequently PD-L1-positive NSCLC, PS, NLR. relationship selected noted.